10 Years of Liquid Biopsy: Igniting a New Era in Precision Oncology

• Highlighting key scientific, technological, and regulatory milestones that have shaped the past decade of liquid biopsy innovation
• Identifying the most pressing challenges that still hinder broader adoption across trial phases, tumor types, and clinical settings
• Outlining the next strategic priorities needed to ensure liquid biopsies become a standard, validated tool for patient selection, monitoring, and treatment optimization in every clinical trial

Speakers:

Jon Baden

Executive Director & Head, Precision Medicine

Bristol Myers Squibb